Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.

Grimm M, Li Y, Brunell SC, Blase E

Postgraduate medicine1 Sept 2013Cited by 5 (Europe PMC)

PMID24113668DOI10.3810/pgm.2013.09.2704PepBankPUB-24113668

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with poorly controlled diabetes, weekly exenatide lowered HbA1c by 2.0% versus 1.6% with basal insulin.
In plain wordsIn patients with poorly controlled diabetes, weekly exenatide reduced HbA1c more than basal insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change
Study
n = 263
Comparator
Pooled insulin glargine and insulin detemir
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−2%
weekly exenatide
HbA1c change
−1.6%
basal insulin
Source sentences
Summary
Treatment with either EQW or b-INS for 26 weeks was associated with significant improvements in HbA1c level compared with baseline, although patients treated with EQW experienced a significantly greater decrease in HbA1c level than those treated with b-INS (least squares [LS] mean ± SE: -2.0% ± 0.08…
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the efficacy and tolerability of exenatide once weekly (EQW) were compared with those of b-INS in patients with type 2 diabetes mellitus and a baseline HbA1c level 8.5% who were undergoing treatment with metformin ± a sulfonylurea.
Summary · context
Data were pooled from two 26-week, randomized, controlled trials (EQW vs insulin glargine and EQW vs insulin detemir [EQW, N = 137; b-INS, N = 126]).
Report a problemFND-2411366801
02HumanRandomized controlled trialEfficacy outcome
In patients with poorly controlled diabetes, weekly exenatide reduced weight by 2.4 kg while basal insulin increased weight by 2.0 kg.
In plain wordsIn patients with poorly controlled diabetes, weight fell with weekly exenatide but rose with basal insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 263
Comparator
Pooled insulin glargine and insulin detemir
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Weight loss
2.4 kg
weekly exenatide
Weight gain
2 kg
basal insulin
Between-group weight difference
−4.4 kg
weekly exenatide versus basal insulin
Source sentences
Summary
Treatment with EQW was associated with a weight loss of 2.4 kg ± 0.23 kg (LS mean ± SE), whereas treatment with b-INS was associated with a weight gain of 2.0 kg ± 0.24 kg (LS mean difference between groups, -4.4 kg ± 0.33; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the efficacy and tolerability of exenatide once weekly (EQW) were compared with those of b-INS in patients with type 2 diabetes mellitus and a baseline HbA1c level 8.5% who were undergoing treatment with metformin ± a sulfonylurea.
Summary · context
Data were pooled from two 26-week, randomized, controlled trials (EQW vs insulin glargine and EQW vs insulin detemir [EQW, N = 137; b-INS, N = 126]).
Report a problemFND-2411366802
03HumanRandomized controlled trialEfficacy outcome
In patients with poorly controlled diabetes, 33.6% with weekly exenatide versus 3.2% with basal insulin achieved the composite endpoint.
In plain wordsIn patients with poorly controlled diabetes, more exenatide patients achieved target HbA1c without weight gain or hypoglycemia than basal insulin patients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseComposite glycemic weight and hypoglycemia endpoint
Study
n = 263
Comparator
Pooled insulin glargine and insulin detemir
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Composite endpoint attainment
33.6%
weekly exenatide
Composite endpoint attainment
3.2%
basal insulin
Source sentences
Summary
Patients in the EQW group were significantly more likely to achieve the composite endpoint of an HbA1c level < 7.0%, no weight gain, and no hypoglycemic events (defined as a blood glucose level < 54 mg/dL requiring self-treatment or assistance to resolve) than patients in the b-INS group (33.6% vs 3.2%; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the efficacy and tolerability of exenatide once weekly (EQW) were compared with those of b-INS in patients with type 2 diabetes mellitus and a baseline HbA1c level 8.5% who were undergoing treatment with metformin ± a sulfonylurea.
Summary · context
Data were pooled from two 26-week, randomized, controlled trials (EQW vs insulin glargine and EQW vs insulin detemir [EQW, N = 137; b-INS, N = 126]).
Report a problemFND-2411366803
04HumanRandomized controlled trialSafety outcome
In patients with poorly controlled diabetes, hypoglycemia rates were 0.08 with weekly exenatide versus 0.37 events per patient-year with basal insulin.
In plain wordsIn patients with poorly controlled diabetes, hypoglycemia was less frequent with weekly exenatide than basal insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHypoglycemic event rate
Study
n = 263
Comparator
Pooled insulin glargine and insulin detemir
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Hypoglycemic event rate
0.08 events per patient-year
weekly exenatide
Hypoglycemic event rate
0.37 events per patient-year
basal insulin
Source sentences
Summary
The exposure-adjusted hypoglycemic event rates were 0.08 and 0.37 events per patient-year in the EQW and b-INS groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the efficacy and tolerability of exenatide once weekly (EQW) were compared with those of b-INS in patients with type 2 diabetes mellitus and a baseline HbA1c level 8.5% who were undergoing treatment with metformin ± a sulfonylurea.
Summary · context
Data were pooled from two 26-week, randomized, controlled trials (EQW vs insulin glargine and EQW vs insulin detemir [EQW, N = 137; b-INS, N = 126]).
Report a problemFND-2411366804
05HumanRandomized controlled trialSafety outcome
In patients with poorly controlled diabetes, gastrointestinal adverse events were more frequent with weekly exenatide than basal insulin.
In plain wordsIn patients with poorly controlled diabetes, digestive adverse events were more frequent with weekly exenatide than basal insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGastrointestinal adverse events
Study
n = 263
Comparator
Pooled insulin glargine and insulin detemir
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events occurred at a higher rate in patients who underwent EQW treatment than those who were treated with b-INS.
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, the efficacy and tolerability of exenatide once weekly (EQW) were compared with those of b-INS in patients with type 2 diabetes mellitus and a baseline HbA1c level 8.5% who were undergoing treatment with metformin ± a sulfonylurea.
Summary · context
Data were pooled from two 26-week, randomized, controlled trials (EQW vs insulin glargine and EQW vs insulin detemir [EQW, N = 137; b-INS, N = 126]).
Report a problemFND-2411366805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.